CVS HEALTH CORP (CVS.DE) Forecast, Price Target & Analyst Ratings
FRA:CVS • US1266501006
67.07 EUR
-0.29 (-0.43%)
Last: Mar 9, 2026, 07:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CVS HEALTH CORP (CVS.DE).
Forecast Snapshot
Consensus Price Target
€81.34
+ 21.28% Upside
Next Earnings Forecast
Release DateApr 29, 2026
PeriodQ1 / 2026
EPS Estimate$2.26
Revenue Estimate96.459B
ChartMill Buy Consensus
79.39%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
€81.34
Upside
+ 21.28%
From current price of €67.07 to mean target of €81.34, Based on 33 analyst forecasts
Low
€67.79
Median
€82.33
High
€93.67
Price Target Revisions
1 Month
1.44%
3 Months
5.88%
Price Target Summary
33 Wall Street analysts provided a forecast for the next 12 months for CVS.DE. The average price target is 81.34 EUR. This implies a price increase of 21.28% is expected in the next year compared to the current price of 67.07.
The average price target has been revised upward by 5.88% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
79.39%
CVS.DE was analyzed by 33 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about CVS.DE.
In the previous month the buy percentage consensus was at a similar level.
CVS.DE was analyzed by 33 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-06-22 | Deutsche Bank | Maintains | Buy |
| 2021-05-19 | BMO Capital | Maintains | Market Perform |
| 2021-05-19 | Wolfe Research | Maintains | Outperform |
| 2021-05-19 | Barclays | Maintains | Overweight |
| 2021-05-19 | Wells Fargo | Initiate | Equal-Weight |
| 2021-05-12 | Mizuho | Maintains | Buy |
| 2021-05-06 | BMO Capital | Maintains | Market Perform |
| 2021-05-06 | Credit Suisse | Maintains | Outperform |
| 2021-05-05 | Raymond James | Maintains | Strong Buy |
| 2021-04-14 | Truist Securities | Maintains | Buy |
| 2021-04-14 | Morgan Stanley | Maintains | Overweight |
| 2021-03-17 | Guggenheim | Downgrade | Buy -> Neutral |
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 29, 2026
PeriodQ1 / 2026
EPS Estimate$2.26
Revenue Estimate96.459B
Revenue Q2Q1.98%
EPS Q2Q0.49%
Number of Analysts23
Next Earnings Revisions
Revenue (1 Month)
-1.61%
Revenue (3 Months)
-4.36%
EPS (1 Month)
-0.21%
EPS (3 Months)
-4.98%
Next Earnings Summary
CVS.DE is expected to report earnings on 4/29/2026. The consensus EPS estimate for the next earnings is 2.26 EUR and the consensus revenue estimate is 96.46B EUR.
The next earnings revenue estimate has been revised downward by 4.36% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 357.776B 10.95% | 372.809B 4.20% | 402.067B 7.85% | 409.619B 1.88% | 428.306B 4.56% | 448.873B 4.80% | 473.107B 5.40% | 493.393B 4.29% | 514.995B 4.38% | 547.437B 6.30% | 581.527B 6.23% | |
| EBITDA YoY % growth | N/A 0.50% | N/A -27.63% | N/A 15.92% | 18.005B 5.29% | 19.98B 10.97% | 22.141B 10.82% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | 15.086B -7.39% | 10.038B -33.46% | 10.502B 4.62% | 15.437B 46.99% | 17.195B 11.39% | 19.105B 11.11% | 21.079B 10.33% | 22.701B 7.69% | N/A | N/A | N/A | |
| Operating Margin | 4.22% | 2.69% | 2.61% | 3.77% | 4.01% | 4.26% | 4.46% | 4.60% | N/A | N/A | N/A | |
| EPS YoY % growth | 8.74 0.46% | 5.42 -37.99% | 6.75 24.54% | 7.25 7.45% | 8.27 14.02% | 9.60 16.14% | 10.39 8.16% | 11.31 8.91% | 12.30 8.73% | 13.61 10.67% | 15.18 11.50% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 2.26 0.49% | 1.84 1.61% | 1.76 10.20% | 1.30 19.59% | 2.61 15.44% | 2.20 19.88% | 1.93 9.31% | 1.51 15.47% |
| Revenue Q2Q % growth | 96.459B 1.98% | 100.841B 1.95% | 106.413B 3.44% | 107.58B 1.79% | 104.572B 8.41% | 109.622B 8.71% | 114.024B 7.15% | 114.595B 6.52% |
| EBITDA Q2Q % growth | 5.163B 19.27% | 4.532B 16.53% | 4.415B 15.55% | 3.506B 12.08% | 5.991B 16.04% | 5.188B 14.47% | 4.507B 2.08% | 4.086B 16.54% |
| EBIT Q2Q % growth | 4.628B 37.17% | 3.925B 64.85% | 3.826B 51.95% | 2.886B 36.65% | 5.235B 13.12% | 4.579B 16.66% | 4.017B 4.99% | 3.276B 13.51% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
12.48%
EPS Next 5 Year
10.88%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
3.58%
Revenue Next 5 Year
4.08%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
15.26%
EBIT Next 5 Year
N/A
CVS HEALTH CORP / CVS.DE Forecast FAQ
Can you provide the average price target for CVS HEALTH CORP stock?
33 analysts have analysed CVS.DE and the average price target is 81.34 EUR. This implies a price increase of 21.28% is expected in the next year compared to the current price of 67.07.
When does CVS HEALTH CORP (CVS.DE) report earnings?
CVS HEALTH CORP (CVS.DE) will report earnings on 2026-04-29, before the market open.
What are the consensus estimates for CVS stock next earnings?
The consensus EPS estimate for the next earnings of CVS HEALTH CORP (CVS.DE) is 2.26 EUR and the consensus revenue estimate is 96.46B EUR.
How many analysts have analysed CVS HEALTH CORP (CVS.DE)?
The number of analysts covering CVS HEALTH CORP (CVS.DE) is 33.